Marcos Castanheira Alegria

home / authors / marcos-castanheira-alegria

Marcos Castanheira Alegria is R&D director at Hypera Pharma.

Articles

Brazilian Regulation of Biosimilar Products: What Is Important to Know

Brazilian Regulation of Biosimilar Products: What Is Important to Know

Sílvia Helena Cestari de Oliveira;Marcos Castanheira Alegria;Marco Antonio Stephano

September 2nd 2022

This article introduces the requirements for a biosimilar license in Brazil and addresses questions about their quality, safety, and efficacy.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: November 15th 2024 | Updated: November 21st 2024

Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs

Published: October 28th 2024 | Updated: November 21st 2024

Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems

Optimizing cGMP Facility Design Space with a Hybrid Approach

Published: October 22nd 2024 | Updated: November 21st 2024

Optimizing cGMP Facility Design Space with a Hybrid Approach

Published: October 28th 2024 | Updated: November 21st 2024

Quantifying Chemotherapeutic Cytotoxicity in Glial Cells using AI-Driven Label-Free Cell Analysis

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.